Abstract
Dyslipidemia is a major risk factor for cardiovascular disease, with increasing numbers of adults being treated with cholesterol-lowering drugs (in particular, statin therapy) to treat elevated low-density lipoprotein cholesterol (LDL-C). Both aerobic exercise training and resistance training are efficacious for altering blood lipid levels, with evidence suggesting that aerobic exercise training raises high-density lipoprotein cholesterol (HDL-C) and lowers triglycerides, and resistance training may be more effective at lowering LDL-C. Consequently, concurrent aerobic and resistance training may be the most effective exercise prescription for improving dyslipidemia, although there is a paucity of randomized control trials addressing exercise dose-response for concurrent aerobic and resistance training and lipid-lipoprotein levels. In addition, exercise training may also potentiate the utility of cholesterol-lowering drugs, and there is limited evidence of interactions between exercise and pharmaceutical interventions that favorably impact hypertension and hyperlipidemia in the same individuals. This chapter summarizes evidence for and clinical considerations surrounding the role of exercise training in treating dyslipidemia.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- ACC:
-
American College of Cardiology
- ACSM:
-
American College of Sports Medicine
- AHA:
-
American Heart Association
- BP:
-
Blood pressure
- CAD:
-
Coronary artery disease
- CHD:
-
Coronary heart disease
- CVD:
-
Cardiovascular disease
- ECS:
-
European Society of Cardiology
- HDL-C:
-
High density lipoprotein cholesterol
- HMG CoA:
-
Hydroxy-methylglutaryl coenzyme A
- LDL-C:
-
Low density lipoprotein cholesterol
- NCEP ATP III:
-
National Cholesterol Education Program Adult Treatment Panel III
- PCSK9:
-
Proprotein convertase subtilisin/kexin type 9
- RAAS:
-
Renin-angiotensin-aldosterone system
- RCT:
-
Randomized controlled trial
- SBP:
-
Systolic blood pressure
- TC:
-
Total cholesterol
- TG:
-
Triglycerides
References
Manual of lipid disorders. 2nd ed. Baltimore: Williams & Wilkins; 1999. p. 2–10.
Wood D, De BG, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis. 1998;140:199–270.
Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720–32.
Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001;285:2486–97.
Jayasinghe R, Craig IH, Mohan RK. Lipoprotein (A) in clinical practice. J Pak Med Assoc. 2014;64:447–50.
Roberts R. Genetics of coronary artery disease. Circ Res. 2014;114:1890–903.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.
Khush KK, Waters D. Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients. Cleve Clin J Med. 2004;71:609–16.
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889–934.
Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498–511.
National Center for Health Statistics. 2014. www.cdc.gov/nchs
Naci H, Ioannidis JP. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ. 2013;347:f5577.
Wong ND, Lopez V, Tang S, Williams GR. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006;98:204–8.
Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–292.
Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311:1416–23.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22.
Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539–40.
Physicians’ Desk Reference. Montvale, Medical Economics; 2002.
Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581–5.
Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96–103.
Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–14.
Rojas-Fernandez CH, Goldstein LB, Levey AI, Taylor BA, Bittner V. An assessment by the Statin Cognitive Safety Task Force: 2014 update. J Clin Lipidol. 2014;8:S5–16.
Durstine JL, Grandjean PW, Davis PG, Ferguson MA, Alderson NL, DuBose KD. Blood lipid and lipoprotein adaptations to exercise: a quantitative analysis. Sports Med. 2001;31:1033–62.
Kuhle CL, Steffen MW, Anderson PJ, Murad MH. Effect of exercise on anthropometric measures and serum lipids in older individuals: a systematic review and meta-analysis. BMJ Open. 2014;4:e005283.
Kelley GA, Kelley KS, Roberts S, Haskell W. Comparison of aerobic exercise, diet or both on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Clin Nutr. 2012;31:156–67.
Kelley GA, Kelley KS, Roberts S, Haskell W. Combined effects of aerobic exercise and diet on lipids and lipoproteins in overweight and obese adults: a meta-analysis. J Obes. 2012;2012:985902.
Lippi G, Schena F, Salvagno GL, Montagnana M, Ballestrieri F, Guidi GC. Comparison of the lipid profile and lipoprotein(a) between sedentary and highly trained subjects. Clin Chem Lab Med. 2006;44:322–6.
Tambalis K, Panagiotakos DB, Kavouras SA, Sidossis LS. Responses of blood lipids to aerobic, resistance, and combined aerobic with resistance exercise training: a systematic review of current evidence. Angiology. 2009;60:614–32.
Kessler HS, Sisson SB, Short KR. The potential for high-intensity interval training to reduce cardiometabolic disease risk. Sports Med. 2012;42:489–509.
Morencos E, Romero B, Peinado AB, et al. Effects of dietary restriction combined with different exercise programs or physical activity recommendations on blood lipids in overweight adults. Nutr Hosp. 2012;27:1916–27.
Kelley GA, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Prev Med. 2009;48:9–19.
Park SK, Park JH, Kwon YC, Kim HS, Yoon MS, Park HT. The effect of combined aerobic and resistance exercise training on abdominal fat in obese middle-aged women. J Physiol Anthropol Appl Human Sci. 2003;22:129–35.
Kodama S, Tanaka S, Saito K, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med. 2007;167:999–1008.
Zmuda JM, Yurgalevitch SM, Flynn MM, et al. Exercise training has little effect on HDL levels and metabolism in men with initially low HDL cholesterol. Atherosclerosis. 1998;137:215–21.
Halbert JA, Silagy CA, Finucane P, Withers RT, Hamdorf PA. Exercise training and blood lipids in hyperlipidemic and normolipidemic adults: a meta-analysis of randomized, controlled trials. Eur J Clin Nutr. 1999;53:514–22.
Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials. Hypertension. 2011;58:950–8.
Paoli A, Pacelli QF, Moro T, et al. Effects of high-intensity circuit training, low-intensity circuit training and endurance training on blood pressure and lipoproteins in middle-aged overweight men. Lipids Health Dis. 2013;12:131.
Arnarson A, Ramel A, Geirsdottir OG, Jonsson PV, Thorsdottir I. Changes in body composition and use of blood cholesterol lowering drugs predict changes in blood lipids during 12 weeks of resistance exercise training in old adults. Aging Clin Exp Res. 2014;26:287–92.
Kokkinos PF, Faselis C, Myers J, Panagiotakos D, Doumas M. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet. 2013;381:394–9.
Sinzinger H, O’Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol. 2004;57:525–8.
Parker BA, Augeri AL, Capizzi JA, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol. 2012;109:282–7.
Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 1997;46:1206–10.
Kostapanos MS, Milionis HJ, Elisaf MS. Current role of statins in the treatment of essential hypertension. Expert Opin Pharmacother. 2010;11:2635–50.
Banach M, Nikfar S, Rahimi R, et al. The effects of statins on blood pressure in normotensive or hypertensive subjects—a meta-analysis of randomized controlled trials. Int J Cardiol. 2013;168:2816–24.
Tonelli M, Sacks F, Pfeffer M, Lopez-Jimenez F, Jhangri GS, Curhan G. Effect of pravastatin on blood pressure in people with cardiovascular disease. J Hum Hypertens. 2006;20:560–5.
Drapala A, Sikora M, Ufvnal M. Statins, the renin-angiotensin-aldosterone system and hypertension—a tale of another beneficial effect of statins. J Renin Angiotensin Aldosterone Syst. 2014;15:250–8.
Maruf FA, Akinpelu AO, Salako BL. A randomized controlled trial of the effects of aerobic dance training on blood lipids among individuals with hypertension on a thiazide. High Blood Press Cardiovasc Prev. 2014;21:275–83.
Bernardes N, Brito JO, Fernandes TG, et al. Pleiotropic effects of simvastatin in physically trained ovariectomized rats. Braz J Med Biol Res. 2013;46:447–53.
Zanchetti A, Liu L, Mancia G, et al. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. J Hypertens. 2014;32:1888–97.
Pescatello LS, Riebe D, Arena R. ΑCSM’s guidelines for exercise testing and prescription. 9th ed. Baltimore: Lippincott Williams & Wilkins; 2013.
Keaney Jr JF, Curfman GD, Jarcho JA. A pragmatic view of the new cholesterol treatment guidelines. N Engl J Med. 2014;370:275–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Taylor, B.A., Zaleski, A., Thompson, P.D. (2015). Effects of Exercise on Lipid-Lipoproteins. In: Pescatello, L. (eds) Effects of Exercise on Hypertension. Molecular and Translational Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-319-17076-3_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-17076-3_13
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-17075-6
Online ISBN: 978-3-319-17076-3
eBook Packages: MedicineMedicine (R0)